What is technetium‑99m methoxy‑isobutyl‑isonitrile (MIBI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 14, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is MIBI?

MIBI (technetium-99m methoxy-isobutyl-isonitrile, also called Tc-99m sestamibi) is a radioactive tracer used in nuclear medicine imaging that is injected intravenously to assess myocardial perfusion, detect coronary artery disease, and evaluate breast tissue and parathyroid glands. 1

Primary Clinical Applications

Cardiac Imaging

  • MIBI is most commonly used for myocardial perfusion scintigraphy (MPS) to diagnose coronary heart disease, assess prognosis, and guide revascularization decisions. 1
  • The tracer is injected during cardiovascular stress (exercise or pharmacological with adenosine or dobutamine) and distributes in the myocardium based on both perfusion and viable myocyte presence. 1
  • Images are acquired using single-photon emission computed tomography (SPECT), with the camera rotating around the patient for 10-20 minutes to create three-dimensional tomographic slices. 1
  • Total patient contact time for stress, injection, and image acquisition is approximately 45 minutes, with stress and rest images typically separated by 3-4 hours. 1

Breast Cancer Screening

  • MIBI is used in molecular breast imaging (MBI) as an emerging supplemental screening tool for women with dense breast tissue, though current evidence remains insufficient for routine use. 1
  • MBI employs dual-head cadmium zinc telluride detectors and takes approximately 40 minutes to complete. 1
  • The cancer detection rate ranges from 7.7 to 8.8 per 1,000 women with dense breasts, with preliminary data showing an incremental detection rate of 9.3 per 1,000. 1
  • Current barriers to widespread adoption include longer examination times, limited studies addressing the spectrum of breast densities and risk, and lack of mortality data. 1

Other Applications

  • MIBI can differentiate between tumor recurrence and radionecrosis in brain imaging following radiotherapy for gliomas. 1
  • Tc-99m MIBI scintigraphy identifies hyperplastic parathyroid glands in patients with renal failure, correctly locating more than 80% of glands when proper reporting methods are used. 2

Mechanism and Pharmacokinetics

Tracer Properties

  • MIBI is avidly extracted by cardiac myocytes, with initial myocardial distribution reflecting both myocyte presence and perfusion. 1
  • The tracer demonstrates rapid blood clearance with early myocardial uptake, and only 5% of the injected dose remains in blood at one hour. 3
  • Peak instantaneous extraction is approximately 0.55, which is lower than thallium-201 (0.83), but MIBI has significantly slower washout rates. 4
  • Initial intense hepatic activity clears into the gallbladder at 1 hour after injection, with optimal target-to-background ratio observed at 60-90 minutes post-injection. 3

Image Interpretation

  • Homogeneous myocardial uptake indicates normal myocardium and perfusion, ruling out clinically significant infarction or coronary stenosis. 1
  • A reversible defect (abnormal on stress, normal at rest) indicates inducible perfusion abnormality corresponding to significant coronary stenosis. 1
  • A fixed defect (abnormal on both stress and rest) indicates loss of viable myocardium, typically from myocardial infarction. 1
  • SPECT imaging with MIBI provides superior image quality compared to thallium-201 in 88% of studies and identifies 79% of stenosed coronary arteries versus 60% with thallium. 5

Radiation Exposure

Dose Ranges

  • The effective radiation dose for cardiac MIBI imaging ranges from 9.8 to 16.3 mSv for a 1-day rest-stress protocol, which is well below the 50 mSv threshold for detectable cancer risk. 6, 7
  • Single injection doses range from 20-30 mCi for cardiac studies. 6
  • For breast imaging, typical doses deliver radiation exposure comparable to or less than natural background radiation. 6

Safety Considerations

  • The thyroid is the critical target organ, receiving approximately 230 mRad/mCi at rest, presumably due to Tc-99m pertechnetate generated in vivo. 3
  • Radiation risk from MIBI diagnostic procedures is considered negligible compared to the clinical benefit of accurate diagnosis. 6
  • Pediatric doses should be weight-adjusted (0.15 mCi/kg for sestamibi, minimum 2 mCi, maximum 10 mCi) due to higher radiation sensitivity in children. 6
  • Maximum fetal absorbed dose following injection is 0.013 mSv, equivalent to one day of natural background radiation, making the risk orders of magnitude below the threshold for fetal harm. 6

Clinical Performance

Diagnostic Accuracy

  • MIBI SPECT with computer quantitation accurately detects significant coronary artery disease non-invasively. 5
  • Studies demonstrate high sensitivity (93%) and specificity (70%) for detecting myocardial infarction using MIBI SPECT imaging. 7
  • MIBI identifies more reversibly ischemic myocardial segments (134) compared to thallium-201 (104), potentially offering better detection of viable but ischemic tissue. 5

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

2
Research

Technetium-99m methoxy isobutyl isonitrile (MIBI) imaging of the parathyroid glands in patients with renal failure.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1997

3
Research

Biodistribution of Tc-99m methoxy-isobutyl-isonitrile (MIBI) in humans.

European journal of nuclear medicine, 1989

6
Guideline

Cancer Risk Associated with Technetium-99m (Tc-99m) in Medical Imaging

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

7
Guideline

Cardiac Imaging Agents

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is MIBI (Methoxyisobutylisonitrile)?
What is the most appropriate action when a 15‑year‑old male patient desires human papillomavirus (HPV) vaccination and his mother consents, but his father objects? a) Administer the vaccine during the visit b) Contact the father before administering the vaccine c) Refer the patient to the county health department for vaccination d) Refuse to administer the vaccine due to the father's disapproval
Can piperacillin‑tazobactam be used alone as empiric therapy for an adult with a purulent skin infection and severe systemic signs, normal renal function, and no β‑lactam allergy?
What is the most effective treatment for classic (idiopathic) trigeminal neuralgia in a 24‑year‑old woman with brief unilateral electric‑shock facial pain, normal neurologic examination, and pending MRI?
Should we obtain orthostatic blood pressure measurements in a 68‑year‑old man with atrial fibrillation status post two catheter ablations and permanent pacemaker who underwent left total hip replacement yesterday, given his supine blood pressure of 128/74 mm Hg and no sitting or standing readings, before he begins ambulation?
In a 58-year-old man with stable vital signs, mild anemia (hemoglobin 12.4 g/dL), and multiple episodes of moderate-volume maroon rectal bleeding with clots, what is the most appropriate next step in management?
How do I document lung findings in an acute COPD exacerbation to reflect inflamed, noisy (rugging) lungs?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question